Methylphenidate (OROS® formulation)

CNS Drugs

Volumn 15, Issue 6, 2001, Pages 495-500

  Keating, Gillian M ^a   McClellan, Karen ^b   Jarvis, Blair ^b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL STIMULANT AGENT; METHYLPHENIDATE; OROS; DOPAMINE UPTAKE INHIBITOR;

ABDOMINAL PAIN; ANOREXIA; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; DRUG TOLERABILITY; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SUSTAINED RELEASE PREPARATION; TREATMENT OUTCOME; VOMITING; ADULT; ARTICLE; CHILD; FEMALE; MALE;

ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CLINICAL TRIALS; DOPAMINE UPTAKE INHIBITORS; FEMALE; HUMANS; MALE; METHYLPHENIDATE;

EID: 0034957115     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200115060-00006     Document Type: Review

References (2)

1. Kimko HC, Cross JT, Abernethy DR. Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet 1999 Dec; 37:457-70
2. Findling RL, Dogin JW. Psychopharmacology of ADHD: children and adolescents. J Clin Psychiatry 1998; 59 Suppl. 7; 42-9